SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc.
MNTA 52.480.0%Oct 2 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: DewDiligence_on_SI4/25/2011 1:42:13 AM
   of 3027
 
MNTA ‘ReadMeFirst’ updated:

NVS reports $247M (!) of 1Q11 Lovenox sales…
…which means at least $70M of 1Q11 Lovenox profit for MNTA;
MNTA’s effective cash balance at 12/31/10 was $203M;
1Q11 EPS forecast by 10nisman;
valuation musings by tinkershaw;
‘cheat sheet’ on MNTA’s income taxes;
musings on (lack of) buyout vig from NVS;
2011-2013 news flow;
Copaxone continues cleaning Tysabri’s clock in US market;
BG-12 data from DEFINE study are impressive;
BG-12 data from CONFIRM study due Sep 2011;
BG-12 is not the same drug as Fumaderm;
musings on BG-12 threat to Copaxone;
Teva might continue detailing Copaxone after generic launch (bullish for MNTA);
musings on a Copaxone authorized generic;
new version of “What’s New in the Anticoagulant Arena?”

siliconinvestor.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News